Clinical trials: Elevated Intraocular Pressure
Open Angle Glaucoma
Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells
The Investigators will compare, in a randomized, prospective, masked and controlled fashion the effect of a non-steroidal anti-inflammatory agent (Acular LS), a corticosteroid (Pred Forte) and a placebo (Refresh Tears) on patient…
- Trial name
- NCT00478036
- Testing
- Acular LS, Pred Forte, Refresh Tears
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Colorado, Denver
Open Angle Glaucoma or Ocular Hypertension
DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
Safety and IOP (intraocular pressure) lowering effect of DE-111 ophthalmic solution will be evaluated in open-angle glaucoma or ocular hypertension patients, in an open-label, multicenter study.
- Trial name
- NCT01343082
- Testing
- DE-111 ophthalmic solution
- Where
- Japan
- Volunteers
- 148 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Glaucoma
Optical Coherence Tomography (OCT) Data Collection Study
Collect OCT data to evaluate the range and age trend of ocular measurements.
- Trial name
- NCT01641835
- Where
- Canada
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- Heidelberg Engineering GmbH
Glaucoma, Open-Angle, Ocular Hypertension
Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.
Phase IV randomized, double blind, multicenter, parallel group clinical study to evaluate the efficacy of the combined use of Krytantek Ofteno PF® and Gaap Ofteno PF®, both applied every 12 hours, versus the use of Eliptic Ofteno…
- Trial name
- PRO-122 (NCT04702789)
- Testing
- Dorzolamide-timolol-brimonidine and latanoprost, Dorzolamide-timolol and latanoprost
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease
A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular Hypertension
A Phase III, Multinational, Multicenter, Investigator-Masked, Randomized, Active-Controlled Trial, comparing the efficacy and safety of DE-130A with Xalatan® in Patients with Open-Angle Glaucoma or Ocular Hypertension over a…
- Trial name
- NCT04133311
- Testing
- DE-130A, Xalatan®, DE-130A/DE-130A
- Where
- France
- Volunteers
- 386 people
- Sponsor
- Santen SAS
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the safety and efficacy of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04024072
- Testing
- Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 495 people
- Sponsor
- Padagis LLC
Glaucoma, Ocular Hypertension
Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®
Comparing Safety and Efficacy of Combigan® and Lumigan® with Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated with Xalatan®.
- Trial name
- NCT01170884
- Testing
- fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Allergan
Glaucoma, Open-Angle
Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated
This study will evaluate the safety and efficacy of bimatoprost/timolol fixed combination (GANfort®) versus latanoprost (Xalatan®) in patients with open-angle glaucoma who have never been previously treated and are at high risk…
- Trial name
- NCT01243567
- Testing
- bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution, latanoprost 0.005% ophthalmic solution
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 81 people
- Sponsor
- Allergan
Ocular Hypertension, Glaucoma
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the ocular and systemic safety of Netarsudil (AR-13324) Ophthalmic Solution, 0.02% q.d. and b.i.d. for 12 months compared to the active comparator Timolol Maleate Ophthalmic Solution, 0.5%.
- Trial name
- NCT02246764
- Testing
- AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Aerie Pharmaceuticals
Primary Open Angle Glaucoma
Evaluation of the XEN Implant in Moderate Primary Open Angle Glaucoma (POAG) Participants
The objective of this study was to evaluate the AqueSys XEN Implant [XEN® Gel Stent (XEN45 Implant)] for the treatment of moderate primary open angle glaucoma (POAG) participants when medications have failed to control…
- Trial name
- NCT02006693
- Testing
- XEN® Gel Stent, Cataract Surgery
- Where
- 21 sites in Austria, Belgium and 7 more
- Volunteers
- 199 people
- Sponsor
- AqueSys, Inc.
Glaucoma
Home Tonometry With the I-care Tonometer for Glaucoma
The overall objective of the study is to scope the self-management for self-monitoring glaucoma using home tonometry.
- Trial name
- NCT02656836
- Testing
- Home tonometry, diagnostic study
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Queen's University, Belfast
Primary Open-angle Glaucoma
Long-term Safety and Performance of the ARGOS-IO Intraocular Pressure Sensor System in Subjects With Primary Open Angle Glaucoma (POAG)
The purpose of this study is to evaluate the long-term safety and performance of the ARGOS-IO system in patients with Primary Open Angle Glaucoma (POAG)
- Trial name
- NCT03651336
- Testing
- ARGOS-IO Sensor Pressure System
- Where
- 4 sites in Germany
- Volunteers
- 16 people
- Sponsor
- Implandata Ophthalmic Products GmbH
Glaucoma
SmartSystem Virtual Reality Headset Perimeter Versus Humphrey HFA-III Perimeter
The goal of this clinical trial is to compare a new device for testing peripheral vision (the SmartSystem virtual reality headset) to the currently most commonly used standard testing device (the Humphrey HFA-III).
- Trial name
- NCT05674890
- Testing
- SmartSystem VR Headset perimeter
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Andrew Pouw, MD
Glaucoma
Human Optokinetic Contrast Device (HOCD) to Measure Visual Function and Identify Patients With and Without Glaucoma
The purpose of this study is to determine if an optokinetic contrast detection device is sufficient to measure contrast sensitivity and to distinguish between patients with and without glaucoma.
- Trial name
- HOCD (NCT02014597)
- Testing
- HOCD
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Benjamin Frankfort, MD, PhD
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension
A single-blind , 12-week, parallel group clinical study is planned to evaluate the efficacy and safety of SPARC0912 and Reference0912.
- Trial name
- NCT00947661
- Testing
- SPARC0912, Reference0912
- Where
- United States
- Volunteers
- 578 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Open-Angle Glaucoma, Ocular Hypertension
Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%
The purpose of this study was to evaluate the efficacy and safety of a fixed combination of Brinzolamide/Brimonidine in lowering intraocular pressure (IOP) relative to each of its individual active components in patients with…
- Trial name
- NCT01297517
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2%
- Volunteers
- 1,001 people
- Sponsor
- Alcon Research
Angle-closure Glaucoma
Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma…
- Trial name
- NCT00762645
- Testing
- Travoprost 0.004% (Travatan), Pilocarpine 1%
- Volunteers
- 30 people
- Sponsor
- Alcon Research
Glaucoma, Neovascular
Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied
The researchers in this trial want to learn how the drug aflibercept works in in Japanese patients with increased eye pressure that is caused by new blood vessels growing in the eye (neovascular glaucoma or NVG).
- Trial name
- VENERA (NCT03639675)
- Testing
- Aflibercept (EYLEA, BAY86-5321), Topical IOP-lowering drugs
- Where
- 7 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Bayer
Glaucoma
Early Feasibility Study of the Brown Glaucoma Implant in Patients With Severe Visual Impairment or No Light Perceived
This is a prospective, non-randomized, single-arm early feasibility study to assess the safety and feasibility of lowering intraocular pressure with the Brown Glaucoma Implant.
- Trial name
- Early Bird (NCT03469297)
- Testing
- Brown Glaucoma Implant
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- MicroOptx
Neovascular Glaucoma
Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
This 52 week study will assess the use of intravitreal aflibercept injections in patients with neovascular glaucoma (NVG) compared to standard of care panretinal photocoagulation.
- Trial name
- NCT01711879
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Colorado, Denver